Literature DB >> 18562081

Overexpression of the PSMB5 gene contributes to bortezomib resistance in T-lymphoblastic lymphoma/leukemia cells derived from Jurkat line.

Shuqing Lü1, Zhilong Chen, Jianmin Yang, Li Chen, Shenglan Gong, Hong Zhou, Lieping Guo, Jianmin Wang.   

Abstract

OBJECTIVE: To study the mechanism of bortezomib resistance in JurkatB lines derived from T-lymphoblastic lymphoma/leukemia Jurkat line.
MATERIALS AND METHODS: Cytotoxicities of popular chemotherapeutic drugs to JurkatB cells were analyzed by trypan blue assay. Functional drug efflux in JurkatB cells was determined by flow cytometry utilizing daunorubicin and the expression of P-glycoprotein (P-gp) was detected by Western blot. mRNA expression levels of proteasome beta5 subunit (PSMB5) were measured by quantitation real-time reverse transcription polymerase chain reaction. In situ hybridization was performed to detect the amplification of PSMB5 gene. The chymotrypsin-like activities were assayed by measuring the release of the fluorescent 7-amido-4-methylcoumarin (AMC) from the substrate N-succinyl-Leu-Leu-Val-Tyr-AMC. Cytogenetic studies were performed using R-banded metaphases and fluorescence in situ hybridization (FISH) analysis. IkappaB-alpha levels were detected by Western blot.
RESULTS: No cross-resistance to daunorubicin, adriamycin, vindesine, and etoposide was found in JurkatB cells. No evidence of drug efflux was found in JurkatB cells and the expression of P-gp was negative. The PSMB5 mRNA was overexpressed in highly resistant JurkatB5 and JurkatB1 lines compared with parental Jurkat, corresponding well with the increase of chymotrypsin-like activity and a karyotype of i(14q). Amplification of PSMB5 gene was demonstrated by in situ hybridization and FISH. The decreased IkappaB-alpha level in JurkatB5 cells after bortezomib treatment indicating an upregulation of nuclear factor-kappaB (NF-kappaB) activity.
CONCLUSION: The mechanism of bortezomib resistance is different from that of multidrug resistance. Overexpression of PSMB5 is an important mechanism for bortezomib resistance in JurkatB lines. NF-kappaB may play a critical role in evading the apoptotic effects.

Entities:  

Mesh:

Substances:

Year:  2008        PMID: 18562081     DOI: 10.1016/j.exphem.2008.04.013

Source DB:  PubMed          Journal:  Exp Hematol        ISSN: 0301-472X            Impact factor:   3.084


  33 in total

1.  Characterization of dihydroartemisinin-resistant colon carcinoma HCT116/R cell line.

Authors:  Jin-Jian Lu; Si-Meng Chen; Jian Ding; Ling-Hua Meng
Journal:  Mol Cell Biochem       Date:  2011-09-30       Impact factor: 3.396

2.  RNAi screen of the druggable genome identifies modulators of proteasome inhibitor sensitivity in myeloma including CDK5.

Authors:  Yuan Xiao Zhu; Rodger Tiedemann; Chang-Xin Shi; Holly Yin; Jessica E Schmidt; Laura A Bruins; Jonathan J Keats; Esteban Braggio; Chris Sereduk; Spyro Mousses; A Keith Stewart
Journal:  Blood       Date:  2011-02-02       Impact factor: 22.113

3.  Apigenin manipulates the ubiquitin-proteasome system to rescue estrogen receptor-β from degradation and induce apoptosis in prostate cancer cells.

Authors:  Vishal Singh; Vikas Sharma; Vikas Verma; Deepti Pandey; Santosh K Yadav; Jagdamba P Maikhuri; Gopal Gupta
Journal:  Eur J Nutr       Date:  2014-11-19       Impact factor: 5.614

Review 4.  The future of proteasome inhibitors in relapsed/refractory multiple myeloma.

Authors:  Robert Z Orlowski
Journal:  Oncology (Williston Park)       Date:  2011-11-15       Impact factor: 2.990

5.  Cytotoxic effects of bortezomib in myelodysplastic syndrome/acute myeloid leukemia depend on autophagy-mediated lysosomal degradation of TRAF6 and repression of PSMA1.

Authors:  Jing Fang; Garrett Rhyasen; Lyndsey Bolanos; Christopher Rasch; Melinda Varney; Mark Wunderlich; Susumu Goyama; Gerrit Jansen; Jacqueline Cloos; Carmela Rigolino; Agostino Cortelezzi; James C Mulloy; Esther N Oliva; Maria Cuzzola; Daniel T Starczynowski
Journal:  Blood       Date:  2012-06-08       Impact factor: 22.113

Review 6.  Targeting the ubiquitin-proteasome system for cancer therapy.

Authors:  Min Shen; Sara Schmitt; Daniela Buac; Q Ping Dou
Journal:  Expert Opin Ther Targets       Date:  2013-07-04       Impact factor: 6.902

7.  PSMB5 plays a dual role in cancer development and immunosuppression.

Authors:  Chih-Yang Wang; Chung-Yen Li; Hui-Ping Hsu; Chien-Yu Cho; Meng-Chi Yen; Tzu-Yang Weng; Wei-Ching Chen; Yu-Hsuan Hung; Kuo-Ting Lee; Jui-Hsiang Hung; Yi-Ling Chen; Ming-Derg Lai
Journal:  Am J Cancer Res       Date:  2017-11-01       Impact factor: 6.166

8.  A reversible and highly selective inhibitor of the proteasomal ubiquitin receptor rpn13 is toxic to multiple myeloma cells.

Authors:  Darci J Trader; Scott Simanski; Thomas Kodadek
Journal:  J Am Chem Soc       Date:  2015-05-08       Impact factor: 15.419

9.  Characterization of bortezomib-adapted I-45 mesothelioma cells.

Authors:  Lidong Zhang; James E Littlejohn; Yu Cui; Xiaobo Cao; Chander Peddaboina; W Roy Smythe
Journal:  Mol Cancer       Date:  2010-05-18       Impact factor: 27.401

10.  The ubiquitin-activating enzyme E1 as a therapeutic target for the treatment of leukemia and multiple myeloma.

Authors:  G Wei Xu; Mohsin Ali; Tabitha E Wood; Derek Wong; Neil Maclean; Xiaoming Wang; Marcela Gronda; Marko Skrtic; Xiaoming Li; Rose Hurren; Xinliang Mao; Meenakshi Venkatesan; Reza Beheshti Zavareh; Troy Ketela; John C Reed; David Rose; Jason Moffat; Robert A Batey; Sirano Dhe-Paganon; Aaron D Schimmer
Journal:  Blood       Date:  2010-01-14       Impact factor: 22.113

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.